KYTRIL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYTRIL is an injectable small-molecule indicated for solid tumors, approved by Roche in 1993. The drug's mechanism of action and specific pharmacological class are unknown from available data. It is administered via injection for oncology patients.
LOE Approaching
Product is approaching loss of exclusivity with modest competitive pressure (30/100), signaling potential team consolidation and shift toward lifecycle management or transition roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
Started Apr 2007
171 enrolled
Post-Operative Nausea and Vomiting
Career Relevance
KYTRIL positions offer career opportunities primarily in manufacturing optimization, supply chain, and operational technology—reflecting a maturing asset in need of cost-efficient production and process improvements. With LOE approaching, career growth is limited to specialty operational and technical roles rather than traditional commercial or clinical positions, making this a stronger fit for process-oriented professionals than brand-building roles.
Manufacturing Biotechnologist
Worked on KYTRIL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.